Eculizumab—a humanized recombinant monoclonal antibody—binds to C5, shows efficacy in managing refractory cases of CAPS [73], post-kidney transplant TMA [74,75], and lupus nephritis with TMA [76]. This evidence concerns the gene C5 and lupus nephritis.